Stifel Nicolaus Cuts TransMedics Group (NASDAQ:TMDX) Price Target to $85.00

TransMedics Group (NASDAQ:TMDX) had its target price trimmed by Stifel Nicolaus from $130.00 to $85.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a hold rating on the stock.

TMDX has been the subject of a number of other reports. JPMorgan Chase & Co. increased their price objective on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Piper Sandler decreased their price objective on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday. Needham & Company LLC decreased their price objective on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday. Oppenheimer cut TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Finally, Wall Street Zen cut TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $135.00.

TransMedics Group Stock Down 6.7%

Shares of NASDAQ TMDX opened at $68.00 on Wednesday. The stock has a market cap of $2.35 billion, a PE ratio of 15.45 and a beta of 2.07. The company has a quick ratio of 6.59, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. TransMedics Group has a 52-week low of $67.69 and a 52-week high of $156.00. The business has a 50-day moving average price of $114.04 and a 200 day moving average price of $125.34.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The firm had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period last year, the company earned $0.70 earnings per share. Equities research analysts forecast that TransMedics Group will post 2.22 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other news, insider Nicholas Corcoran sold 2,966 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $412,629.92. Following the completion of the transaction, the insider directly owned 29,831 shares of the company’s stock, valued at approximately $4,150,088.72. This represents a 9.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Stephanie Lovell sold 1,193 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total value of $178,496.66. Following the transaction, the director directly owned 2,866 shares of the company’s stock, valued at approximately $428,810.92. This trade represents a 29.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 16,205 shares of company stock worth $2,353,002. 6.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

Large investors have recently modified their holdings of the business. Whittier Trust Co. of Nevada Inc. raised its stake in shares of TransMedics Group by 981.0% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after buying an additional 206 shares in the last quarter. Harvest Fund Management Co. Ltd purchased a new position in shares of TransMedics Group during the 3rd quarter worth approximately $29,000. Allworth Financial LP raised its stake in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after buying an additional 113 shares in the last quarter. Optiver Holding B.V. raised its stake in shares of TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after buying an additional 191 shares in the last quarter. Finally, Parallel Advisors LLC raised its stake in shares of TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.